An Empirical Assessment of COVID-19’s Impact on the Financial Performance of Small-Cap Pharmaceutical Companies in India
Abstract
The COVID-19 pandemic, an unprecedented global health and economic crisis, profoundly disrupted businesses across the world, including India’s crucial pharmaceutical sector. While large pharmaceutical multinationals have dominated pandemic-era research and policy attention, there has been comparatively little empirical work on Small and Medium Enterprises (SMEs), which constitute the backbone of India’s pharmaceutical manufacturing capacity. This study seeks to fill this gap by analysing the impact of COVID-19 on the financial performance of three representative Indian pharmaceutical SMEs—Jagsonpal Pharmaceuticals Ltd, FDC Ltd, and Lincoln Pharmaceuticals Ltd—through rigorous pre-pandemic (2017–2019) and post-pandemic (2020–2022) financial analysis. Adopting a descriptive and comparative research design, the paper leverages secondary data sourced from company annual reports, stock exchange filings, and verified financial databases. Key financial performance indicators—profitability (Net Profit Margin, Return on Equity, Return on Assets), liquidity (Current Ratio, Quick Ratio), and solvency (Debt-to-Equity Ratio)—were calculated and compared over the study periods. Statistical validation was performed using paired t-tests to assess the significance of pre- and post-pandemic changes. The conceptual framework draws upon theories of SME resilience, particularly the Resource-Based View and Dynamic Capabilities Theory, to interpret results beyond simple ratio movement. Findings reveal that, although all three SMEs exhibited improved profitability, stronger liquidity, and reduced leverage following the pandemic, these changes were not statistically significant at the 5% confidence level. The patterns suggest that strategic cost management, operational restructuring, and diversification of supply chains—rather than the direct effects of the pandemic—were key drivers of financial improvement. Jagsonpal’s marked recovery is linked to internal financial controls and product realignment, while Lincoln’s stability derives from cash management and rapid debt reduction. The research underscores the need for targeted policy support, digital transformation incentives, and indigenous API development to secure India’s pharmaceutical supply chain and export competitiveness in a post-pandemic world.
How to Cite This Article
Aliasgar Abbasbhai Vohra (2025). An Empirical Assessment of COVID-19’s Impact on the Financial Performance of Small-Cap Pharmaceutical Companies in India . International Journal of Multidisciplinary Research and Growth Evaluation (IJMRGE), 6(4), 1358-1365. DOI: https://doi.org/10.54660/IJMRGE.2025.6.4.1358-1365
References
- 1. Bhavyasri MYVS, Mohapatra LM. Financialperformanceanalysisofselected Indianpharmaceuticalcompaniesduring COVID-19outbreak. In: Pandya FH, International Journalof Multidisciplinary Researchand Growth Evaluationwww. allmultidisciplinaryjournal. com1365|Page Jain S, Atchyutuni N, editors. Building Resilient Organizations.1sted. Routledge;2022. p.61-73.
- 2. Chandna A, Jain S, Vohra S. Challengesof Indian Pharmaceutical Industriesto Meet World Requirementduring COVID-19 Pandemic. Asian Pac JHealth Sci.2022;9(4\:194-202.
- 3. Gautam A, Madhavi T. Assessing Financial Performance: ARatio Analysisof Selected Pharmaceutical Companiesin India. Evergreen.2024;11(3\:1481-92.
- 4. Khurana MK, Sharma S, Bhargava N. The Impactof Financial Ratiosand Pandemicon Firm Performance: An Indian Economic Study. In: Sharma H, Chakravorty A, Hussain S, Kumari R, editors. Artificial Intelligence: Theoryand Applications. Vol.
- 844. Springer Nature Singapore;2024. p.41-51.
- 5. Lahkar G, Baiju H, Marwaha D, Daniel NA. Barrierstobusinessgrowthinpharmaceutical SMEs Asustainableperspective. Int JProd Qual Manag.2023;39(2\:137-70.
- 6. Ministryof MSME. Annual Reporton Micro, Small, andcited2024https://msme. gov. in
- 7. Pap?kov?L, Pap?k M. Intellectualcapitalanditsimpactson SMEsprofitabilityduring COVID-19pandemic. JEast Eur Cent Asian Res.2022;9(3\:521-31.
- 8. Roy A, Saha T. Assessingthe Liquidity Positionof Selected Pharmaceutical Companiesin India: AComparative Analysis Beforeand After COVID-
- 19. Int JSci Res Eng Manag.2024;08(05\:1-5.
- 9. Saunders M, Lewis P, Thornhill A. Researchmethodsforbusinessstudents.8thed. Pearson Education;2019.
- 10. Smith HK. The Impactof COVID-19on Supply Chain
- 11. Vyas N, Joshi A, Malviya S, Kharia A. Reduced Pharma Supply Chainin COVID-19: Meas Reliancefor Active Pharmaceutical Ingredientson Chinaandother Countries. Indian JPharm Educ Res.2020;54(4\:835-42.
- 12. Yin RK. Casestudyresearchandapplications: Designandmethods.6thed. Sage Publications;2018.